You are here

Cerecor Receives Fast Track Designation from FDA for CERC-801 for the Treatment of PGM1 Deficiency

ROCKVILLE, Md., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug Administration (FDA) has designated Fast Track Designation for CERC-801, an ultra-pure, oral formulation of D-galactose currently in development for the treatment of Phosphoglucomutase 1 (PGM1) deficiency, also known as PGM1-CDG.
Tuesday, February 19, 2019 - 08:27